Showing 1511-1520 of 1697 results for "".
- Anti-Tau Antibody Etalanetug Shows Reductions in Novel Biomarker of Tau Tangle Pathology in Dominantly Inherited Alzheimer Diseasehttps://practicalneurology.com/news/anti-tau-antibody-etalanetug-shows-reductions-in-novel-biomarker-of-tau-tangle-pathology-in-dominantly-inherited-alzheimer-disease/2484712/Treatment with the investigational anti-tau antibody etalanetug (E2814; Eisai, Tokyo, Japan) for individuals with dominantly inherited Alzheimer disease (DIAD) was associated with reductions in eMTBR-tau243, a novel cerebrospinal fluid (CSF) biomarker that reflects tau tangle pathology and consis
- Intrathecal Gene Therapy Approved for Adults, Older Children with Spinal Muscular Atrophyhttps://practicalneurology.com/news/intrathecal-gene-therapy-approved-for-adults-older-children-with-spinal-muscular-atrophy/2484610/The Food and Drug Administration has approved Itvisma (onasemnogene abeparvovec-brve; Novartis, Basel, Switzerland) for the treatment of people aged 2 years and older with spinal muscular atrophy (SMA) and a confirmed survival motor neuron 1 (SMN1) gene mutation. The adeno-associated vir
- Artificial Sweeteners Linked to Faster Cognitive Decline in Midlife Adultshttps://practicalneurology.com/news/artificial-sweeteners-linked-to-faster-cognitive-decline-in-midlife-adults/2484026/Higher consumption of low- and no-calorie sweeteners (LNCSs) was associated with accelerated cognitive decline, particularly in verbal fluency and global cognition, among adults aged <60 years. This finding from a longitudinal study published in Neurology contributes to a growing body
- Lower Amyloid Levels after Donanemab Treatment Correlated with Slower Clinical Declinehttps://practicalneurology.com/news/lower-amyloid-levels-after-donanemab-treatment-correlated-with-slower-clinical-decline/2484005/A secondary analysis of results from the TRAILBLAZER-ALZ 2 phase 3 trial (NCT04437511) published in JAMA Neurology demonstrated an association between lower posttreatment amyloid plaque levels and slower cognitive and functional decline in individuals with early Alzheimer disease (AD) tr
- Gene Therapy for Rett Syndrome Receives FDA Breakthrough Therapy Designationhttps://practicalneurology.com/news/gene-therapy-for-rett-syndrome-granted-fda-breakthrough-therapy-designation/2483962/The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to TSHA-102 (Taysha Gene Therapies, Dallas, TX) for the treatment of individuals with Rett syndrome. TSHA-102 is an intrathecally delivered adeno-associated virus 9 (AAV9) gene transfer therapy designed to mediate
- Long COVID “Brain Fog” May Be Linked to an Underlying Molecular Mechanismhttps://practicalneurology.com/news/long-covid-brain-fog-may-be-linked-to-an-underlying-molecular-mechanism/2483959/Cognitive impairment associated with the reported chronic condition often referred to as “long COVID” may be linked to an underlying molecular mechanism characterized by increased α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor density across the brain according to new findi
- Study Evaluates Botox as Essential Tremor Treatmenthttps://practicalneurology.com/news/study-evaluates-botox-as-essential-tremor-treatment/2483937/Treatment with Botox (onabotulinumtoxinA; AbbVie, North Chicago, IL) was associated with significant improvements in functional outcomes in people with upper limb essential tremor (ET) compared with placebo in study results presented at the 2025 International Congress of Parkinson’s Disease and M
- Long-Term Data Support Ravulizumab for NMOSDhttps://practicalneurology.com/news/long-term-data-support-ravulizumab-for-nmosd/2483586/Final analysis of results from the long-term extension of the CHAMPION-NMOSD clinical trial (NCT04201262) showed that treatment with Ultomiris (ravulizumab; Alexion—AstraZeneca Rare Disease, Boston, MA) was associated with relapse prevention and stable or improved disability outcomes in adults wi
- Study Examines Effects of Chemotherapy in Individuals with Cancer and MShttps://practicalneurology.com/news/study-examines-effects-of-chemotherapy-in-individuals-with-cancer-and-ms/2483538/New findings from an analysis of data from the MSBase registry (MSBase.org) suggest that chemotherapy for cancer may be associated with a temporary protective effect against multiple sclerosis (MS) relapses, offering clinicians important real-world insights on disease-modifying therapy (DMT) mana
- Anti-CD20 Therapies Outperform Platform DMTs in Pediatric MShttps://practicalneurology.com/news/high-efficacy-anti-cd20-vs-platform-therapies-in-prepubertal-pediatric-ms/2483537/Anti-CD20 therapies were associated with superior outcomes compared with traditional platform disease-modifying treatments (DMTs) for children with prepubertal-onset multiple sclerosis (MS) according to study results presented at the 41st Congress of the European Committee for Treatment and Resea